Bifidobacterium longum BB536 DSM 20219

Bifidobacterium longum BB536 (DSM 20219) is a clinically studied probiotic strain that modulates gut microbiota composition and immune signaling through production of short-chain fatty acids and interaction with intestinal toll-like receptors. It demonstrates documented benefits for constipation relief, ulcerative colitis remission, and restoration of beneficial Bifidobacterium and Lactobacillus populations in the colon.

Origin & History

Bifidobacterium longum BB536 DSM 20219 is a specific strain of probiotic bacterium naturally found in the human intestinal microbiota, particularly in infants and adults. It is industrially cultured via fermentation and processed into powders or capsules, with DSM 20219 as its deposit number in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) culture collection.

Historical & Cultural Context

No historical or traditional medicine use is documented in the research. BB536 is a modern, commercially developed clinical probiotic strain without ties to traditional healing systems.

Health Benefits

• Improves bowel movement frequency in constipated adults (moderate evidence from double-blind crossover trial, n=24, PMC9636538)
• Supports ulcerative colitis remission with 63% achieving remission vs 52% placebo (moderate evidence from multicenter RCT, PMID: 26418574)
• Increases beneficial gut bacteria ratio (bifidobacteria/Enterobacteriaceae) in infants (preliminary evidence from infant trial, PMC10012958)
• Shows trend toward improved immune markers (serum IgA) in elderly (preliminary evidence from RCT, n=45, PMID: 23192454)
• May reduce visceral and total body fat when combined with B. breve (preliminary evidence from RCT, PMID: 38542727)

How It Works

B. longum BB536 ferments dietary fibers into short-chain fatty acids (SCFAs), primarily acetate and butyrate, which fuel colonocytes and lower luminal pH to inhibit pathogenic bacteria. The strain modulates mucosal immunity by signaling through Toll-like receptor 2 (TLR2) and TLR4 on intestinal epithelial and dendritic cells, promoting regulatory T-cell differentiation and reducing pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, BB536 produces bacteriocin-like inhibitory substances and competes for epithelial adhesion sites, reinforcing the intestinal barrier and reducing gut permeability.

Scientific Research

Clinical trials include double-blind RCTs in elderly tube-fed patients (n=45, PMID: 23192454), constipated adults (n=24, PMC9636538), ulcerative colitis patients (PMID: 26418574), and elderly with chronic constipation (n=80, PMID: 36216361). Studies consistently show increased fecal bifidobacteria counts and improvements in digestive health, though primary endpoints sometimes miss statistical significance.

Clinical Summary

A double-blind crossover RCT (n=24, PMC9636538) demonstrated that BB536 supplementation significantly improved bowel movement frequency in constipated adults compared to placebo. A multicenter RCT (PMID: 26418574) found that 63% of ulcerative colitis patients achieved remission with BB536 versus 52% in the placebo group, suggesting moderate benefit as adjunct therapy. Human trials also document measurable increases in fecal Bifidobacterium and Lactobacillus counts following supplementation, indicating favorable microbiota modulation. Overall evidence is moderate in strength, derived primarily from small-to-medium RCTs; larger confirmatory trials are needed for several indications.

Nutritional Profile

Bifidobacterium longum BB536 (DSM 20219) is a non-caloric, non-macronutrient ingredient delivered as viable bacterial cells. Typical commercial preparations contain 1–10 billion CFU (colony-forming units) per serving dose, with exact CFU varying by product format. The ingredient itself contributes negligible protein (~0.1–0.5 mg/serving from bacterial cell mass), no dietary fat, and no digestible carbohydrates. Bioactive compounds intrinsic to this strain include: (1) Exopolysaccharides (EPS) produced by BB536, which modulate immune signaling via Toll-like receptor pathways and contribute to mucosal adhesion; (2) Short-chain fatty acid (SCFA) precursor activity — BB536 ferments dietary fibers to produce acetate and lactate as primary metabolic end-products, with acetate output estimated at 1–5 mmol per 10^9 CFU in colonic conditions; (3) Bacteriocin-like inhibitory substances (BLIS) that suppress pathogenic Enterobacteriaceae growth; (4) Cell wall components including lipoteichoic acids and peptidoglycans that interact with host pattern recognition receptors. The strain does not synthesize measurable quantities of B vitamins under standard gut colonization conditions, unlike some other Bifidobacterium species. Bioavailability is defined by colonization efficiency: BB536 demonstrates moderate gastric acid and bile salt tolerance, with approximately 40–60% of ingested cells surviving transit to the colon based on fecal recovery studies. Viability is maintained in freeze-dried powder form at moisture content below 5% and storage temperatures at or below 25°C.

Preparation & Dosage

Clinically studied doses range from 5×10¹⁰ CFU/day in powder form for elderly constipation to acid-resistant capsules for adult constipation. Most trials use once-daily administration for 2-12 weeks. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Bifidobacterium breve MCC1274, Prebiotics (FOS/GOS), Vitamin D, Zinc, Lactobacillus acidophilus

Safety & Interactions

B. longum BB536 is generally recognized as safe (GRAS) and well-tolerated in healthy adults, with adverse effects in clinical trials limited to transient mild bloating or flatulence during the initial days of supplementation. Immunocompromised individuals, including those on high-dose corticosteroids, biologics, or post-organ transplant immunosuppressants, should use live probiotic strains cautiously due to a theoretical risk of bacteremia. Concurrent use with broad-spectrum antibiotics such as fluoroquinolones or amoxicillin-clavulanate may significantly reduce viable bacterial counts and diminish efficacy; separating doses by at least 2 hours is recommended. Pregnancy and lactation safety data are limited but no significant adverse events have been reported in available studies; consultation with a healthcare provider is advised.